Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Synergistic effect of nanoparticles with probiotics on gastrointestinal regenerative medicine
Francisco, A.M
January 2026: Amgen completed Phase 3 enrollment for MariTide (AMG 133) in the MARITIME-Obesity trial, with interim efficacy data expected in Q3 2026 that will position the monthly injection GLP-1/GIP antagonist as a once-monthly obesity treatment alternative
Moreover, data from human multipotent adipose-derived stem cells treated with T3 during differentiation showed an increase of UCP1 expression together with increased mitochondrial biogenesis [112]
It's time to execute
US$ 27.52
US$ 28.39
US$ 23.20
US$ 28.04
US$ 26.95
US$ 29.51
US$ 27.72
US$ 27.49
